Short Summary
The Delhi High Court granted an ad interim ex-parte injunction in favor of Dr. Reddys Laboratories Limited against Pro Bios Pharmaceuticals Pvt. Ltd. The dispute centered on the unauthorized use and copying of the registered trademark 'OMEZ' for the medicinal preparation OMEPRAZOLE. The court found that the plaintiff had made out a prima facie case, noting both trademark infringement ('OMZES') and copying of packaging, thereby preventing irreparable loss to Dr. Reddys.
Detailed Summary
In the pharmaceutical world, a brand name is more than a label — it is a promise of trust, quality, and patient safety. When a competitor copies not just the name but the very look of a medicine on the shelf, the stakes rise far beyond ordinary trademark disputes. The case of Dr. Reddy's Laboratories versus Pro Bios Pharmaceuticals is a striking example of how courts can move decisively when a brand's identity is brazenly cloned, and what it takes for a plaintiff to secure immediate relief.
Dr. Reddy's Laboratories Limited, a well-established pharmaceutical company, had built its reputation around the registered trademark 'OMEZ', used for its medicinal preparation OMEPRAZOLE. Through continuous and longstanding use, the brand had become a recognizable name in the market. Pro Bios Pharmaceuticals Pvt. Ltd., the defendant, entered the picture with a strikingly similar mark — 'OMZES' — for what appeared to be a comparable product. The similarity did not stop at the name. The defendant had also mimicked the packaging of Dr. Reddy's product, creating an overall impression that could easily mislead consumers at the pharmacy shelf. Faced with this unauthorized imitation, Dr. Reddy's approached the Delhi High Court seeking urgent intervention to protect its registered rights and prevent further damage to its brand.
Dr. Reddy's argued that it held a valid registration for the trademark 'OMEZ' and that the defendant's use of 'OMZES' constituted clear trademark infringement. The plaintiff emphasized that the similarity between the two marks was not merely phonetic but extended to the visual presentation of the product, including the packaging design. This dual layer of copying — both the mark and the trade dress — was presented as evidence of an intent to ride on the goodwill of the established brand and to create confusion among consumers, particularly at the point of purchase. The defendant, appearing to have offered no substantive counter at this stage, faced the weight of a registered right, established market presence, and demonstrable copying. The legal friction centered on whether the plaintiff had done enough to convince the court that immediate intervention was warranted before the defendant could be heard.
The Delhi High Court found that Dr. Reddy's had succeeded in establishing a prima facie case in its favor. The court recognized both the trademark infringement arising from the use of 'OMZES' and the copying of the plaintiff's packaging as serious concerns. Acknowledging that allowing the defendant to continue selling under these circumstances would cause irreparable loss to Dr. Reddy's, the court granted an ad interim ex-parte injunction. This meant that the defendant was immediately restrained from using the infringing mark and copied packaging, even before a full hearing on the merits could take place. The court's reasoning underscored the strength of registered trademark rights, the value of continuous use in building protectable goodwill, and the critical role of packaging similarity in establishing consumer confusion.
For founders and IP professionals in the pharmaceutical space, this case delivers a clear and actionable lesson: a registered trademark alone is powerful, but combining it with evidence of continuous use, established goodwill, and demonstrable consumer confusion — including through packaging similarity — dramatically strengthens the case for urgent relief. When a competitor copies not just your name but your entire visual identity, do not wait. Move quickly, present a complete picture of your rights and the imitation, and the courts can act decisively to protect your brand before the damage becomes irreversible.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court - Orders. Understanding the court's reasoning in Dr. Reddys Laboratories Limited vs Pro Bios Pharmaceuticals Pvt. Ltd. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
The North Face Apparel CorpvsController of Patents and Designs
The North Face Apparel Corp challenged the Controller of Patents' refusal of its patent application (No. 202147026139) titled 'Systems and Methods for End-to-End Article Management' before the Madras High Court under Section 117A of the Patents Act, 1970. The Controller had rejected the application citing lack of inventive step over prior art documents D21-D24. The Court held that the Controller erred by dissecting the claims into isolated elements rather than assessing the invention as a whole, and overlooked the use of spectrophotometer and invisible markers for tracking the manufacturing process, which were not disclosed in the cited prior art. The appeal was allowed and the Controller was directed to grant the patent.
Aventose Energy Private LimitedvsThe Assistant Controller of Patents & Designs, Patent Office Chennai
Aventose Energy Private Limited appealed under Section 117A of the Patents Act, 1970 against the refusal of its patent application (No. 202141019671) for a 'System and Method for Operating Automobiles with an Electric Drivetrain' featuring safe mode activation upon fault detection. The Madras High Court found that the Assistant Controller had contradicted the First Examination Report (which accepted novelty) by subsequently holding the invention lacked novelty without giving the applicant an opportunity to be heard. The court further held that the Controller improperly conflated novelty with inventive step under Section 2(1)(ja) and failed to properly analyze the claims against prior art documents D1–D4.
Apex Laboratories Pvt LtdvsElder Lifescience and Ambico Ayurvedic Health Care
Apex Laboratories Pvt Ltd, the prior adopter and registered proprietor of the trademark ZINCOVIT (TM No. 487453 in Class 5) since 1988, sought interim injunction against Elder Lifescience and Ambico Ayurvedic Health Care for using the deceptively similar mark NEO ZINCOVIT. The applicant also claimed copyright infringement of its registered artistic works (A-108878/2014) covering colour scheme, get-up, and layout. The Madras High Court was satisfied that the respondents were attempting to piggyback on the applicant's goodwill and granted interim injunctions on all three applications covering trademark infringement, copyright infringement, and passing off.
Radico Khaitan LimitedvsPicadilly Agro Industries Limited
This Special Leave Petition arose from a judgment dated 29-05-2026 in CS No. 8/2025 passed by the District Judge, Karnal, Haryana, concerning a trademark dispute over the marks 'Cashmere' and 'Kashmyr' used in relation to beer and vodka. The Supreme Court noted that a First Appeal (FAO-COM-11-2026) was already pending before the Division Bench of the Punjab and Haryana High Court, listed for 28.10.2026. The Court disposed of the SLP without adjudicating it on merits, requesting the High Court to pass an appropriate order regarding the ad interim injunction on the scheduled date.
Maharaja Agrasen Technical Educational Society (Regd.)vsMaharaja Agrasen Himalayan Garhwal University
The plaintiff, Maharaja Agrasen Technical Educational Society, filed a suit for permanent injunction against the defendant, Maharaja Agrasen Himalayan Garhwal University, alleging infringement and passing off regarding the use of the words 'Maharaja Agrasen' in the defendant's name. The Delhi High Court had previously granted a restraint order on 10.07.2026. During the pendency of the suit, the parties arrived at a settlement dated 14.09.2026, under which the defendant agreed to change its name through a statutory amendment while being permitted limited transitional use of its existing name. The court recorded the settlement, modified the interim order accordingly, and listed the matter for compliance reporting on 13.07.2027.
Varahi Diamonds And Finance LimitedvsSahil Vinay Mehra Trading As Mehra Sons Jewellers & Anr.
This is a commercial suit filed by Varahi Diamonds And Finance Limited against Sahil Vinay Mehra Trading As Mehra Sons Jewellers & Anr. before the Delhi High Court. The order is primarily procedural, dealing with the registration of the plaint, issuance of summons, directions for filing pleadings, and an interim injunction application. The matter was referred to mediation, with parties directed to appear before the Delhi High Court Mediation and Conciliation Centre.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.